Editorial Picks
Hand-picked stories offering depth, insight, and perspective on global cannabis developments.
Editorial Picks · page 12
- CBD Market
Medicare CBD Coverage Proposed, But Federal Ban Threatens Entire Industry
Cannabis stocks enjoyed another spike last week following reports that the Centers for Medicare & Medicaid Services is preparing to authorise insurance coverage for CBD products under certain Medicare programs, even as the same products face an existential threat from recently passed federal legislation.
- Industry Trends
Kanabo Calls in Administrators, Marking Sobering End to LSE Cannabis Rush
UK medical cannabis operator Kanabo Group has fallen into administration, seeing the last remaining member of the first four cannabis pioneers onto the London Stock Exchange face collapse.
- Clinical Research
Ananda Exits Landmark NHS-Funded Epilepsy Trial and Public Markets
Ananda Pharma, one of the UK’s leading clinical-stage pharmaceutical cannabis companies, has announced a string of strategic pivots, including stepping away from a flagship UK clinical trial into epilepsy.
- Clinical Research
Cannabis Health Symposium 2025 – Key Takeaways Part 2
The afternoon sessions at Tuesday’s inaugural Cannabis Health Symposium 2025 moved beyond the fundamentals of cannabis medicine and its potential, to the practical realities of prescribing this relatively new medicine in the UK.
- Clinical Research
Cannabis Health Symposium 2025 – Key Takeaways Part 1
On Tuesday, November 25, nearly 200 healthcare professionals, patient advocates, cannabis educators, and industry leaders converged on London’s Conway Hall for the inaugural Cannabis Health Symposium.
- Hemp Industry
UK Court Throws Out CBD Case Over Improper Testing, but Operators ‘More Vulnerable Than Ever’
A UK Crown Court has thrown out criminal charges against CBD hemp flower importers after ruling that police mishandled evidence and used improper testing methods, but only after a five-and-a-half-year ordeal that destroyed the defendants’ businesses and forced them to relocate abroad.
- Industry Trends
Bundesrat Backs Tighter Cannabis Prescribing Rules, Rejects Mail-Order Penalties
Germany’s Bundesrat voted on November 21 to support key restrictions on medical cannabis prescribing and distribution, while rejecting proposals to ban prescriptions being sent via mail, a mixed outcome that offers both relief and concern for an industry bracing for regulatory tightening.
- Clinical Research
EU ‘Intoxicating Hemp’ Review Highlights Major Knowledge Gaps Behind Blanket Bans
Last week, the US government voted to impose a blanket ban on all so-called ‘intoxicating hemp’ substances, ending what has been a contentious and long-running battle to regulate the recent emergence of THC substitutes.
- CBD Market
Trump Ends Intoxicating Hemp Era, But Unintended Victims and Repeal Efforts Signal Turbulent Year Ahead
The sweeping redefinition of ‘hemp’ in the US following the passage of the funding bill threatens non-intoxicating CBD processors while pushing consumers toward unregulated markets President Donald Trump signed legislation on November 12 that brought the longest government shutdown in history to an end.
- Industry Trends
Germany Medical Cannabis Imports Surge a Further 19%, but Are Looming Curbs Actually Boosting Demand?
Germany’s medical cannabis imports continued their historic run in Q3 of 2025, seeing the country bring in just under 57 tonnes, though growth levels dipped slightly from Q2.
- Industry Trends
Is Portugal About to Lose its Position as the ‘Gateway’ to Europe’s Largest Cannabis Markets?
Over the last five years, Portugal has built a reputation as the medical cannabis ‘doorway to Europe’, the go-to hub for countries from North and South America, Asia and Oceania to ship their cannabis to and have it distributed to Europe’s most active markets.
- Events
Business of Cannabis: New York 2025 – Key Takeaways
Business of Cannabis: New York 2025 arrived at a crucial moment not just for the local cannabis industry, but for the entire state.
